Global Hormonal Infertility Market - Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Upcoming Report
  • May 2020
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hormonal Infertility Market By Gland (Hypothalamus, Ovaries, Pituitary Gland, Others), Hormones (Luteinizing Hormone, Kisspeptin, Others), Diseases (Polycystic Ovary Syndrome, Pituitary Tumors, Diabetes, Menopause, Cushing’s Syndrome, STDs, Polyps & Fibroids, Others), Diagnosis (Ultrasound, Blood & Urine Tests, Hysterosalpingography, Ovarian Reserve Testing, Others), Treatment (Medication, Surgery, Assisted Reproductive Technology, Others), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U. A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027.

Hormonal Infertility Market

Market Analysis and Insights: Global Hormonal Infertility Market

Hormonal infertility market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of reproductive hormones diseases worldwide and emerging markets are the factors responsible for the growth of this market.

Growing cases of fluctuating hormone levels drives the hormonal infertility market. Several reasons can cause hormonal infertility in females such as irregular or absent menstrual periods, lowered levels of LH and FSH, damaged in reproductive organ (including; fallopian tubes, uterus & cervix), presence of diseases (such as; tumor, cyst, STDs or birth defects), stress and alcohol and drugs use will also boost up the hormonal infertility market. However, rising prevalence of reproductive hormones diseases in women’s, increased use of alcohol, drugs use, increased use of birth control pills and increased awareness towards female reproductive health is also boosts hormonal infertility market. Furthermore, lack of female reproductive health awareness in developing countries may hamper the global hormonal infertility market.

Hormonal infertility is the condition in which hormonal decline and imbalance are natural occurrences that can cause physical, mental, and emotional problems. Infertility is the inability of a sexually active couple unsuccessful in efforts to conceive over the course of one full year without taking any birth control pills. When the causes present in female, it is referred to as female infertility. 

This hormonal infertility market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Hormonal Infertility Market Scope and Market Size

The hormonal infertility market is segmented on the basis of gland, hormones, diseases, diagnosis, treatment, route of administration, end-users and distribution channel.

  • On the basis of gland, the hormonal infertility market is segmented into hypothalamus, ovaries, pituitary gland and others
  • On the basis of hormones, the hormonal infertility market is segmented into luteinizing hormone, kisspeptin and others
  • On the basis of diseases, the hormonal infertility market is segmented into polycystic ovary syndrome, pituitary tumors, diabetes, menopause, cushing’s syndrome, STDs, polyps & fibroids and others
  • On the basis of diagnosis, the hormonal infertility market is segmented into ultrasound, blood & urine tests, hysterosalpingography, ovarian reserve testing and others
  • On the basis of treatment, the hormonal infertility market is segmented into medication, surgery, assisted reproductive technology and others. Medication further segmented into clomiphene, aromatase inhibitors, GnRH, LH, or FSH injections, intrauterine insemination and others.
  • Route of administration segment of hormonal infertility market is segmented into oral, parenteral, implants and others
  • On the basis of end-users, the hormonal infertility market is segmented into hospitals, specialty clinics and others
  • On the basis of distribution channel, hormonal infertility market has also been segmented into hospital pharmacy, retail pharmacy, others.

Hormonal Infertility Market Country Level Analysis

Hormonal infertility market is analysed and market size information is provided by country, gland, hormones, diseases, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hormonal infertility market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, Saudi Arabia, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America anticipated the largest market share due to increasing hormones related diseases in women’s and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation. Europe is considered to be second largest market for hormonal infertility due to increased reproductive disorders in women and increased alcohol & drugs uses. Asia-Pacific is expected to account for the largest market share over coming years for the hormonal infertility market due increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturer.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Hormonal infertility market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Hormonal Infertility Market Share Analysis

Hormonal infertility market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hormonal infertility market.

The major players covered in the hormonal infertility market are Par Pharmaceutical, Allergan, Arbor Pharmaceuticals, TerSera Therapeutics LLC., Novartis AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceuticals Industries Ltd., AbbVie Inc., and EMD Serono, Inc., among others.

Customization Available: Global Hormonal Infertility Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19